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BACKGROUND: Glioblastoma multiforme (GBM) is  a  human  malignant  brain  tumor  which is arise from glial cells. Our previous study proved 
that GBM cells proliferation increased after treating 
by  conditioned  medium of  umbilical  cord-derived 
mesenchymal stem cells (CM-UCSCs). Cells proliferation 
is probably mediated by tumor necrosis factor (TNF)-α 
which could bind to membrane receptor and induce 
signaling pathway. Therefore, this research was intended to 
analyze the mRNA expression of TNF-α signaling pathway 
molecules on CM-treated GBM cells by measuring TNF 
receptor 1 and 2 (TNFR1 and TNFR2), TNFR associated 
factor 2 (TRAF2), nuclear factor kappa B (NF-κB) mRNA 
level, and TNFR2 protein level.
METHODS: UCSCs and human glioblastoma T98G 
cells were cultured and harvested after 80% confluence. 
CM was prepared by growing UCSCs in serum alpha 
Minimum Essential Media (α-MEM) for 24 hours. Fifty 
percent concentration of CM-UCSCs was used to treat 
T98G  cells  for  24  hours.  TNF-α  level  in  CM-UCSC 
was  detected  using  enzyme  linked-immunosorbent  assay 
(ELISA), while the expression of TNFR1, TNFR2, TRAF2 
and NF-κB  were  detected  using  quantitative  Reverse 
Transcriptase Polymerase Chain Reaction (qRT-PCR), 
and TNFR2  protein  level  was detected  using sandwich 
ELISA. 
RESULTS: TNF-α level was detected in CM-UCSCs 
4.4 pg/mL. Moreover, the expression of TNFR1, TNFR2, 
TRAF2 and NF-κB were significantly 1.4-fold, 4.9-fold, 
5.6-fold, 1.8-fold respectively higher in T98G treated cells 
than control. TNFR2 protein level in T98G treated cells was 
11.57 pg/mg protein higher than control.
CONCLUSION: The expression of molecules involved in 
TNF-α signaling pathway were up regulated in T98G cells 
treated by CM-UCSCs. 
KEywORDS:  CM-UCSCs,  TNFR1,  TNFR2,  TRAF2, 
NF-κB, T98G cells 
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Abstract
Introduction
Glioblastoma multiforme (GBM) is the primary malignant 
brain tumor that originates from glial cells and it develops 
mostly in the brain hemisphere. Until now the etiology 
of GBM is not known with certainty. The heterogeneity 
of glioblastoma cell formers resulted in lower successful 
therapeutic.(1) One of the factors that is considered to 
affect glioma growth is the role of tumor microenvironment 
(TME) which have multiple properties.(2) Mesenchymal 
stem cells (MSCs) as a part of tumor microenvironment 
secrete various growth factors, cytokines, chemokines 
which is called secretome that could increase proliferation 
and metastasis of tumors and also promote apoptosis through 
paracrine interactions.(3) According to previous study found 
Print ISSN: 2085-3297, Online ISSN: 2355-9179The Indonesian Biomedical Journal, Vol.11, No.2, August 2019, p.217-24
218
that apoptosis occurred in glioblastoma cells treated with 
umbilical cord stem cells (UCSC) by direct co culture.(4) 
But in other study reported that treating glioblastoma U251 
cell with secretome from human umbilical cord perivascular 
cells (HUCPCs) lead to increase viability, survival, and 
migration of glioblastoma cells.(5)  
 Tumor necrosis factor (TNF)-α is a cytokine which 
could be found in secretome has various role in the host 
immune defense system, inflammation process, cancer cells 
progression and metastasis.(6) TNF has a dual role in the 
development of cancer cells either increase cell apoptosis 
or increase cancer cell proliferation.(7) TNF which are 
secreted by MSCs, is synthesized as a molecule propeptide 
26 kDa which are bound to transmembrane (tm-TNF). TNF 
is cleaved by TNF activating converting enzyme (TACE)  to 
become  active  form  molecule  17  kDa  which  are called 
soluble TNF (sTNF). Both of these molecules can act as 
ligand on TNF receptors (TNFR). There are two types of 
TNFR namely TNFR1 and TNFR2. Both of these receptors 
have different function in cell signaling so the response 
depends on activation ligand which secreted in TME.(8) 
The basic difference between TNFR1 and TNFR2 is the 
location of the death domain (DD) in the cytoplasm of the 
cell. TNFR1 has DD region so that if the TNF molecule 
binds to its receptor, a cell apoptosis response will occur. 
Whereas TNFR2 does not have the region of DD so the 
response arises in the form of cell proliferation. TNFR1 also 
has another ability to activate the cell proliferation pathway 
through the recruitment of the adapter protein TNFR 
associated factor 2 (TRAF2) and protein nuclear factor 
kappa B (NF-κB) when TNF binds to TNFR1.(9) 
 There  are  a  few  studies  which  discuss  the 
enhancement of GBM cells proliferation after treating by 
conditioned medium (CM) of MSCs. Recent study found 
that cell viability, tumor growth and proliferation cells of 
U251 glioblastoma cells increased after treating by CM of 
human umbilical cord perivascular cells (HUCPVCs).(5) 
Another study using two groups of breast cancer cell lines 
such as MDA-MB-468 and SK-BR3 showed that TNF-α 
could contributed in development of cancer cells progression 
through the TNFR1-NF-κB axis.(10) Our  previous study 
conclude that treated T98G cells with CM of MSCs could 
rise pluripotency marker such as Sex determining region 
Y box 2 (SOX2), Octamer binding transcription factor 4 
(OCT-4), and homeobox Nanog protein.(11) In addition, 
our another study proved that CM-UCSCs does not seems 
affect apoptosis but tend to increase cell proliferation in 
T98G cells.(12) Nevertheless, signaling cascade pathway 
in GBM cells treated with CM of umbilical cord-derived 
mesenchymal stem cells (UCMSC) is not well established. 
Therefore, this research aims to detect the presence TNF-α 
molecule in CM-UCMSC and it’s signaling cascade 
pathway regulation by measuring mRNA level of TNFR1, 
TNFR2, TRAF2 and NF-κB collected from GBM that had 
been previously treated by CM-UCMSC.
Methods
Culture of Glioblastoma T98G Cells
Glioblastoma T98G cells (American type culture collection 
(ATCC)) Number CRL-1690TM) were provided from 
our previous research.(13) GBM cells were grown in 
Gibco Dulbecco’s Modified Eagle Medium (DMEM) high 
glucose (Thermo Fisher Scientific, Massachusetts, USA) on 
T-Flask 25 cm2 with the addition of Sodium bicarbonate, 
10% fetal bovine serum, 1% penicillin-streptomycin, 1% 
amphotericin. Culture cells were placed in incubator with 
5% CO2, 37oC temperature and 95% O2 conditions. Cells 
were grown until the 80% subconfluence and then harvested. 
Medium was replaced every 3 days.(13) 
Culture of UCSCs and Preparation of CM
UCSCs were provided from our preious research (11) which 
were grown in a Gibco α-Minimum Essential Medium 
(α-MEM) (Thermo Fisher Scientific) on a 25 cm2 T-Flask 
with 10 % fetal bovine serum, 1% penicillin-streptomycin, 
and 1% amphotericin. Culture cells were placed in chamber 
with 37oC, 5% saturation CO2, and 95% saturation O2. Cells 
were grown to 80% confluence. Conditioned medium was 
prepared by growing UCSCs in serum free α-MEM for 
24 hours. UCSCs were removed and medium was taken 
and filtered, then diluted for 50% (v/v) using DMEM high 
glucose. Fifty percent concentration of CM-UCSCs was 
used to treat T98G cells for 24 hours.  Control T98G cells 
were cultured with α-MEM and DMEM with ratio 1:1. CM 
treated cells means T98G cells were cultured with CM-
UCSCs and α-MEM with ratio 1:1.(14)
Protein Sample Preparation
Protein isolation was done by radio immunoprecipitation 
assay (RIPA) buffer (Thermo Fisher Scientific) through the 
protocol kit. Twenty-five μL was added into CM-treated 
T98G cells with 225  cold phosphate buffered saline (PBS). 
Then, micro tube was incubated with ice for 30 minutes 
and vortexed every 10 minutes. After that, micro tube was 
centrifuged in 12.000 rpm, 4oC, for 10 minutes. Supernatant 
was removed into another micro tube and put in -80oC.  
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Enzyme Linked Imunoabsorbance Assay (ELISA) of 
TNF-α and TNFR2
TNF-α level from conditioned medium was measured using 
sandwich ELISA method with  human ELISA TNF-α assay 
kit (Catalogue #E-EL-H0109, Elabscience, Texas, USA). 
Meanwhile, TNFR2 level was measured using sandwich 
ELISA method with human ELISA TNFR2 assay kit 
(Catalogue #Ab 100643, Abcam, Cambridge, USA). All 
procedures were performed according to kit protocol. The 
plate was read using Varioscan® ELISA reader (Thermo 
Fisher Scientific) in the absorbance 450 nm. TNF-α and 
TNFR2 concentrations were calculated based on standard 
curve plotted. 
RNA Isolation and Quantitative Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR)
TriPure Isolation (Roche, Basel, Switzerland) reagent was 
used to isolate of total RNA of condition medium-treated 
glioblastoma multiforme cells according to kit protocol. 
Relative mRNA expression of TNF-α signaling pathway 
were detected using SensiFAST SYBR® No ROX Real 
Time PCR kits (Bioline, Nottingham, United Kingdom) and 
run in Applied Biosystem 7500 q-PCR machine (Thermo 
Fisher Scientific). All samples were done in triplicate and 
the expressions were calculated using delta CT method.
(13) Annealing temperature for TNFR1, TRAF2 and NF-κB 
were 55oC while annealing temperature TNFR2 was 60oC. 
Annealing temperature reference gene 18sRNA was 59oC. 
List of primers were provided in Table 1.
Statistical Analysis
Statistical test analysis was performed using student 
t-test. The experiment was carried out three times. Data 
Primer Sequences Amplicon References
TNFR1 Forward 5’ TGC CTA CCC CAG ATT GAG AA 3’ 169 bp (15)
Reverse 5’ ATT TCC CAC AAA CAA TGG AGT AG 3’
TNFR2 Forward 5’ ATT CTG GGA GGA AGC AGG TT 3’ 236 bp (4)
Reverse 5’ AGC CAG CCA GTC TGA CAT CT 3’
TRAF2 Forward 5’ CAC ACC TGT CCC TCT TCT TTG 3’ 100 bp (16)
Reverse 5’ TTC TGG TCG AGC AGC ATT AAG 3’
NFκB Forward 5’ CGC TTA GGA GGG AGA GCC CA 3’ 190 bp (17)
Reverse 5’ TGG GCC ATC TGT TGG CAG TG 3’
18s RNA Forward 5’ AAA CGG CTA CCA CAT CCA AG 3’ 155 bp (18)
Reverse 5’ CCT CCA ATG GAT CCT CGT TA 3’
Gene
Tabel 1. List of primers sequences.
analysis was calculated with IBM SPSS software 23 (IBM 
Corporation, New York, USA)
TNF-α protein was detected in CM-UCSC. TNF-α level was 
detected 4.4 pg/mL in CM-UCSCs. There was no significant 
morphology changes on T98G GBM cells (Figure 1) after 
24 hours incubation with 50% CM-MSC (v/v).
 TNFR1, TNFR2, TRAF2 and NF-κB mRNA 
expression were significantly higher in CM-UCSCs. In 
Figure 2,3,4, the ratio of mRNA expression in T98G GMB 
cells treated with CM-UCSCs were higher 1.4-fold, 5.6-
fold, and 1.8-fold, respectively, than control. The increasing 
of  those  mRNA  expression  probable  occurred  due  to 
binding of TNF in CM with TNFR1 in membrane which 
made a recruitment to TRAF2 and NFκB intracellularly. 
However, the binding of TNF-α to its receptor should be 
proved using Electrophoretic mobility shift assay (EMSA).
 TNFR2 protein level were significantly higher in 
CM-UCSCs treated cells than control. TNFR2 protein level 
in CM-treated T98G cells was 11.57 pg/mg protein while 
TNFR2 protein level in control medium was 7.72 pg/mg 
protein. This findings also revealed higher mRNA TNFR2 
parallel with higher protein level in glioblastoma CM-
treated cells.
Results
Discussion
Our research proved that TNF-α was detected 4.4 pg/mL in 
CM-UCMSCs. Although the detection range of the ELISA 
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Figure 1. No changes in morphological of T98G cells with 24 hours incubation. A: control T98G cells with 50% concentration of 
α-MEM and DMEM  (v/v); B: CM-treated T98G cells with the 50% concentration of CM and α-MEM (v/v). White bar: 213 µm.
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Figure 2. TNFR1 and TNFR2 mRNA expression. Total RNA in the amount of 100 ng from glioblastoma T98G cell was amplified using 
qRT-PCR to detect TNFR1 and TNFR2 mRNA expression. The expression was measured with Livak method with 18s RNA as reference 
gene. TNFR1 expression was 1.4-fold *(p=0.038), TNFR2 expression was 4.9-fold **(p=0.001). TNFR2 mRNA expression 3.3-fold 
significantly higher than TNFR1 ***(p=0.000). All data displayed in mean±SE (n=9). Control means T98G cells were cultured with 
α-MEM and DMEM with ratio 1:1. CM treated cells means T98G cells were cultured with CM-UCSCs and α-MEM with ratio 1:1.
incubation  with  umbilical cord derived MSCs.  Expression 
of TNF α signaling pathway (TNFR1, TNFR2, TRAF2-
NFκB mRNA) was upregulated in CM-treated T98G cells. 
The mRNA expression of TNFR2 was significantly higher 
compared to TNFR1 mRNA expression.  Moreover, TNFR2 
protein level was significantly higher in CM-treated T98G 
cells compared to control.
kit was 7.81-500 pg/mL, however the sensitivity of the 
kit was 4.6 pg/mL. Therefore, TNF-α in our CM could be 
still detected. The low level of TNF-α in our CM probably 
due to the short duration of CM collection (only 24 hours 
collection). In other study, TNF-α was detected 8.5±3.5 pg/
mL after 14 days collection.(19) There was no significant 
morphological changes T98G GBM cells after 24 hours 
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Figure 3. TRAF2 mRNA expression. 
Total RNA in the amount of 100 ng from 
glioblastoma T98G cell was amplified using 
qRT-PCR to detect TRAF2 mRNA expression. 
The expression was measured with Livak 
method with 18s RNA as reference gene. 
TRAF2 expression was 5.6-fold **(p=0.001). 
All data was displayed in mean±SE  (n=8). 
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Figure 4. NF-κB mRNA expression. 
Total RNA in the amount of 100 ng from 
glioblastoma T98G cell was amplified using 
qRT-PCR to detect NF-kB mRNA expression. 
The expression was measured with Livak 
method with 18s RNA as reference gene. NF-
kB expression was 1.8-fold **(p=0.001). All 
data was displayed in mean±SE (n=8). 
 TNF-α is a cytokines which can act in inflammation and 
host immune defense which contained in the TME. Proteins 
and MSCs could influence cell viability, proliferation and 
metastasis of cancer cells. In different circumstances, proteins 
in the TME could also increase apoptosis. Impressive study 
using rat with fibrosarcoma proved that administration of 
TNF combined with chemotherapy agents could damage 
blood vessels followed by entering the chemotherapeutic 
substances into the tissue around the tumor which cause 
apoptosis of tumor cells.(20) However another study found 
that TNF-α could promote chemoresistance in breast cancer. 
Moreover, TNF-α could promote cancer cell proliferation 
through TNFR1-NF-κB axis.(10)
 Our discovery found that TNF-α cytokines was 
detected in CM-UCSCs. It indicated that umbilical cord 
derived MSCs secrete this cytokine which probable play a 
role in tumor growth and cells proliferation. Interesting study 
about CM-UCMSCs cell showed that cytokine, chemokine 
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Figure 5. TNFR2 level protein. Protein 
sample in the amount of 100 μL was used 
to measure TNFR2 level using ELISA with 
sandwich ELISA method. Protein TNFR2 
level concentration was measured with 
absorbance 450 nm. TNFR2 concentration 
in CM treated T98G cells was 11.57 pg/mg 
protein while concentration in control was 
7.72 pg/mg protein **(p=0.001). All data 
displayed in mean±SE (n=6). 
and growth factors such as TNF-α and interleukin (IL-6) play 
a role in tissue healing and inflammation.(19) Another study 
using GBM cells showed that cytokine and chemokine in 
CM-UCMSCs could make interaction with the GBM cells 
through paracrine communication which supported cancer 
stem cell (CSC) glioblastoma growth.(21) 
 By knowing the content of the CM, it could be 
predicted the signaling pathway of this molecule which 
support our previous finding about the enhancement of 
GBM cells proliferation after treating by CM-UCSCs. The 
existence of TNF-α in CM probably could activate signaling 
pathway of GBM cells proliferation through binding of 
TNF-α with its receptors (TNFR1 and TNFR2 receptors) 
that was indicated by up regulation of TNFR1, TNFR2, 
TRAF2 and NFκB mRNA expression in this research. 
Interesting study using human UCSC and their exosome 
vesicles could increase lung adenocarcinoma growth in vivo 
which injected to nude mice.(22) Recently, study from colon 
cancer found that treated HCT-116 cells with TNF-α lead 
to invasion and migration cancer cells. It was activated by 
extracellular receptor kinase (ERK)1/2 pathway which up 
regulated trophoblast cell surface antigen 2 (TROP2) protein 
level.(23) Our previous study proved that T98G GBM cells 
treated with CM-UCSCs tend to increase proliferation cells. 
However there’s no significant effect on apoptosis cells in 
T98G cells control and CM-treated.(12) From Figure 1, 
we can conclude that there was no morphological changes 
with T98G glioblastoma multiforme cells treated with CM-
UCSC. However, it seemed that CM-treated T98G cells tend 
to more proliferate than control after 24 hours incubation. 
 From Figure 2, the increased of TNFR1 and TNFR2 
expression probably could activate cell proliferation 
signaling pathways, particularly through the recruitment of 
adapter proteins in the cytoplasm, TRAF. TNFR2 expression 
higher 3.3-fold than TNFR1 because affinity TNF-α to 
bind with TNFR2 was 5 times higher than TNFR1.(24) 
When TNF α bind to TNF receptor, they could activate 
protein adaptor in cytoplasm. TNFR1 could activate TNF 
receptor associated death domain (TRADD) then activated 
apoptosis pathway through caspase protein. Another 
activation by TRADD was recruited TRAF2 (TNF receptor 
associated factor 2) which could lead activation of NF-κB as 
transcription factor in cell survival, cancer progression, and 
metastasis.(25) At the same time, the binding of TNF-α to 
TNFR2 will recruit TRAF2 and lead to activation of NFκB 
as transcription factor.
 Figure 3 proved that TRAF2 was recruited, probably 
due to binding of TNF ɑ with TNFR1 and TNFR2. 
Recruitment TRAF2 protein adapter in the cytoplasm 
resulted recruitment of other proteins that generate cell 
proliferation signals such as NF-κB which was proved by 
increasing its expression (Figure 4). NF-κB is one of the 
protein adaptor which is recruited through TRAF2 activation. 
A prostate cancer study showed that up regulation of TRAF2 
associated with poor recurrence of metastatic cancer.(16) 
TNF-α which contained in CM could induce NF-κB through 
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canonical pathway. Lately, breast cancer study proved that 
higher NF-κB expression lead to proliferation of MDA-
MB-468.(10) 
 Up regulation of TNFR2 expression in our research 
could activate NF-κB expression as a transcription factors 
which regulate cell survival, proliferation and metastasis. 
According to previous study found that NFκB has a role 
in maintenance glioblastoma cancer stem cell which causes 
up regulation of pluripotency marker, chemo resistance, and 
low survival rate.(26) Therefore, NF-κB could be targeted 
as therapeutic molecule that suppression of NF-κB made 
tumor growth slower.(27) In our study, the increase of 
TNFR2 mRNA expression was followed by increasing of 
TNFR2 protein level as shown in Figure 5. Breast cancer 
study proved that TNF-α which bind to TNFR2 could 
increase phosphorylation of protein adaptor p38, JNK 
and ERK.(28) Activation of TNFR2 caused recruitment 
of mitogen-activated protein kinases (MAPK), ERK, 
and NF-κB pathway that lead to stimulate proliferation 
response. The protein level of TNFR2 was 4 times higher 
than TNFR1 in human epithelial cells treated by TNF-α and 
lovastatin.(29) The limitation of this study is expression 
analysis of molecules involved in TNF-α signaling pathway 
only measured at mRNA level, except for TNFR2. Protein 
expression analysis should be measured to ensure that this 
treatment also affect protein level.  In addition, further 
research is needed by blocking TNF-α using specific 
inhibitor to prove that the TNF-α signaling pathway is truly 
induced by this treatment.
Conclusion
There  was  an  increase  of  TNF-α  receptor,  TRAF2  and 
NF-κB mRNA expression in GBM cells treated by CM-
UCSCs.
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